Methimazole-Induced Agranulocytosis

ABSTRACT

The antithyroid drug methimazole is used to treat patients with hyperthyroidism. Agranulocytosis is a rare and life-threatening adverse effect of the drug, characterized by a reduced circulating white blood cell count, which increases the risk of infections. We present the case of a 49-year-old male patient with a known history of hyperthyroidism for 10 years who was on tablet methimazole 10 mg three times daily. He presented with complaints of high-grade fever associated with chills for 2 days, sweating, body myalgias, difficulty in speaking due to neck swelling and palpitations. Laboratory investigations revealed severe neutropenia along with a thyrotoxic crisis. The patient's symptoms and laboratory abnormalities resolved after withdrawal of the drug, and he was managed with broad-spectrum antibiotics, propranolol, hydrocortisone, and cholestyramine. His neutrophil count normalized within 1 week. This case report highlights the importance of early identification of methimazole-induced agranulocytosis. Clinicians should maintain a high index of suspicion for rare life-threatening complications, of antithyroid drugs in patients presenting with infectious symptoms. Management of methimazole -induced agranulocytosis mainly involves discontinuation of the drug for preventing mortality associated with ATD-induced agranulocytosis.

KEYWORDS

• Agranulocytosis
• Methimazole
• Hyperthyroidism
• Thyrotoxic crisis

Showing references and in-text citations exactly as published.

• DOI10.5530/ijopp.20260688Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPP.

• Article · VOLUME 19, ISSUE 3A Case Lichen Planus Pigmentosus an Uncommon Entity with Distinctive Characteristics: A Case ReportMuhammed Salah, Muhammed Shas, Nahdha K, Shariba Parveen, Anjali C S, Kameswaran R, Sirajudheen M K · pp. 389–391Case ReportSame type: Article
• Article · VOLUME 19, ISSUE 3A Challenging Case of High-Risk Pediatric AML with Novel ZNF348/SF11 Fusion and Mixed Phenotypic Features: Navigating Genomic Complexity, Resistant Infections, and MRD-Driven Therapy toward RemissionC. Dhandapani, Kavitha A · pp. 392–394Case ReportSame type: Article
• Article · VOLUME 19, ISSUE 3Fixed Drug Eruption Caused by EtoricoxibNiya Catherine · pp. 395–396Case ReportSame type: Article
• Article · VOLUME 19, ISSUE 3A Case of Dry Gangrene in an Autoimmune Patient: Diagnostic and Therapeutic ChallengesParshant Pokhriyal, Muskan Kumari, Damini Kharb, Subodh Gururani, Anuj Nautiyal · pp. 397–402Case ReportSame type: Article